LC
BTAI icon

Lindbrook Capital’s BioXcel Therapeutics BTAI Stock Holding History

Lindbrook Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$147 – 2698
2023
Q2 		$147 Hold
1
– – ﹤0.01% 2660
2023
Q1 		$411 Buy
+1
New +$427 ﹤0.01% 2639
2022
Q2 		– Sell
-6
Closed -$2K – 2506
2022
Q1 		$2K Buy
+6
New +$1.74K ﹤0.01% 1945
2021
Q4 		– Sell
-125
Closed -$61K – 2082
2021
Q3 		$61K Buy
125
+94
+303% +$41.3K 0.02% 388
2021
Q2 		$15K Sell
31
-17
-35% -$9.27K ﹤0.01% 881
2021
Q1 		$33K Buy
48
+36
+300% +$29K 0.01% 569
2020
Q4 		$9K Sell
12
-113
-90% -$88K ﹤0.01% 937
2020
Q3 		$87K Buy
+125
New +$93.9K 0.02% 233

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's BTAI Position: Q3 2023 in Review

Lindbrook Capital sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 1 share — an estimated $147 sold.

Lindbrook Capital first reported a position in BTAI in Q3 2020 and held it in 8 quarters. The position peaked at $87K in Q3 2020. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Lindbrook Capital reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lindbrook Capital sold 1 BioXcel Therapeutics share in Q3 2023, an estimated $147.
  • Lindbrook Capital first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 8 quarters.
  • Lindbrook Capital's BioXcel Therapeutics position peaked at $87K in Q3 2020.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Lindbrook Capital's 13F filing for Q3 2023, filed 25 Oct 2023.